Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Tabata, T. Terada, R. Tabata, T. Nakano (Nishinimiya, Amagasaki, Japan). Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. Eur Respir J 2012; 40: Suppl. 56, 4619

Member's Comments

No comment yet.

Related content which might interest you: Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Soluble mesothelin as a monitoring tool for malignant mesothelioma patients Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours Year: 2009 Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 Diagnostic usefulness of C reactive protein levels in pleural effusions of malignant and non malignant origin Source: Eur Respir J 2007; 30: Suppl. 51, 431s Year: 2007 Diagnostic value of procalcitonin and C-reactive protein in the differentiation among bening and malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma Source: Annual Congress 2008 - Inorganic dust exposure and the lung Year: 2008 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Diagnostic usefulness of tumour markers in pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003 The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 C-reactive protein in differentiation between tuberculous and malignant pleural effusions Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Diagnostic and prognostic significance of survivin levels in malignant pleural effusion Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011